首頁 > 市場調查報告書 > 製藥

分子標靶治療學

市場調查報告書

商品編碼

2108983

全球標靶蛋白水解劑（PROTAC）市場：市場機會、已通過核准藥物銷售、定價、技術平台和臨床試驗洞察（2030 年）

Global PROTAC Targeted Protein Degraders Market Opportunity, Approved Drug Sales, Pricing, Technology Platforms, & Clinical Trials Insight 2030

出版日期: 2026年08月01日 | 出版商:

KuicK Research | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球標靶蛋白水解劑（PROTAC）市場－市場機會、已通過核准藥物銷售、定價、技術平台和臨床試驗洞察（2030 年）報告結果和亮點

全球標靶蛋白水解劑（PROTAC）市場機會：預計2030年將超過15億美元
全面了解 PROTAC 藥物的臨床試驗：超過 140 種產品。
依公司、國家、適應症和臨床試驗階段分析全球 PROTAC 藥物臨床試驗。
快速通道和孤兒藥認定現狀的洞察
依地區和適應症分析PROTAC藥物市場趨勢。
公司專屬專有技術平台
競爭格局

PROTAC療法的必要性及本報告的意義

PROTAC介導的特定標靶蛋白分解是近年來藥物研發領域最有前景的突破之一。 PROTAC不僅作用於標靶蛋白的功能，還能選擇性地去除致病蛋白，為攻克包括腫瘤學、免疫學、神經科學和感染疾病在內的多種疾病領域的難題提供了一種新的途徑。這個領域已從一個充滿前景的學術概念發展成為一種成熟的新型療法開發方法，這得益於藥物化學、結構生物學、電腦輔助藥物發現、連接子設計和E3連接酶生物學等領域的進步。 FDA對首批PROTAC的核准以及臨床階段藥物研發管線的進展進一步凸顯了該平台在藥物研發領域的創新性。

本報告全面回顧了全球PROTAC市場格局，涵蓋技術平台、藥物發現方法、競爭格局、臨床開發、合作關係和商業性前景。報告還評估了製藥公司、生物技術公司、大學和技術供應商等關鍵參與者對標靶蛋白分解未來發展的影響。此外，報告也指出了在標靶蛋白分解領域中眾多新興的商業機遇，這些機會有望吸引投資、合作、授權和產品組合拓展等方面的關注。對於希望深入了解精準醫療領域最具發展前景的趨勢之一的製藥業專業人士和投資者而言，本報告將是一份寶貴的資訊來源。

報告中包含了對臨床試驗的深入分析。

臨床開發仍是PROTAC藥物未來商業性前景的重要指標。近期，多個治療領域的許多候選藥物已從臨床前研究進入臨床試驗階段，顯示人們對這項技術的信心日益增強。本報告全面概述了目前的臨床藥物研發管線，包括處於不同研發階段的臨床項目，以及適應症、標靶分子、申辦者、作用機制、研發階段和地理分佈等資訊。

本報告分析了腫瘤學及其他治療領域目前正在研究的單藥療法和聯合治療。報告重點關注聯合治療，這些療法結合了內分泌療法、激酶抑製劑、免疫療法、標靶治療、化療以及用於提高療效和克服抗藥性的新型藥物。此外，報告還詳細資訊介紹了贊助、開發、進行標靶蛋白水解療法臨床前和臨床試驗的公司和機構，從而深入剖析了目前的臨床生態系統。

領先的PROTAC療法研發公司

目前，標靶蛋白水解療法領域的競爭格局包括大型製藥企業、前景看好的生物技術公司、合約研究機構和頂尖學術機構。率先開發該療法的公司證明，分解劑可以口服給藥，並以蛋白質分解的形式應用於臨床。這為目前產品線的擴展奠定了基礎。此後，許多公司紛紛加入該領域的競爭，開發各自的平台、新型E3連接酶、組織特異性分解劑、滲透性血腦屏障的化合物以及新的分解技術。

除了各公司自主研發新藥之外，許多公司也積極投資於電腦輔助藥物發現、人工智慧、蛋白質體學、結構生物學、配體發現和生物標記等基礎技術。授權授權、合作研究、創業融資和收購等活動持續增強該領域的商業潛力，並推動多個治療領域的創新。

技術平台、合作研究和合約

技術平台正成為標靶蛋白分解領域的關鍵差異化因素。各公司正在建造藥物發現引擎，這些引擎不僅能夠設計自身的候選藥物，還能實施針對不同類型蛋白質的各種方案。這些平台利用藥物化學、結構生物學、計算建模、連接子設計與最佳化、配體發現、人工智慧、蛋白質體學、藥物動力學建模以及E3連接酶生物學等技術，加速分解劑的發現與最佳化。

另一個有趣的例子是Arvinas公司的「PROTAC發現引擎」，它將生物目標、專有的E3連接酶技術、高通量化學、結構生物學、人工智慧、配體生成技術和轉化藥理學整合到一個單一的藥物發現引擎中。該平台使該公司成功開發出多個臨床候選藥物，包括可口服、生物利用度高且能穿過血腦屏障的化合物，並開發出首個透過PROTAC機制發揮作用的FDA認證核可藥。

策略聯盟也成為創新過程中的另一個關鍵要素。製藥公司、生物技術公司、學術研究機構、人工智慧公司和受託研究機構（CRO）之間的合作日益增多，匯聚了標靶發現、藥物化學、臨床開發、生物標記開發和精準醫療等領域的專業知識。預計這一趨勢將繼續塑造PROTAC領域的未來發展。

一份概述 PROTAC 療法未來發展方向的報告。

此外，標靶蛋白水解療法的未來應用範圍預計將遠超過第一代針對多種癌症的藥物。新型E3連接酶的發現、組織特異性分解工具的開發、動態的改進、中樞神經系統遞送、口服生物有效性的提高以及基於生物標記的精準患者篩選，都將有助於拓展PROTACs在多種疾病中的應用領域。分子膠、人工智慧在分解劑發現中的應用以及創新遞送技術等最新進展也將進一步推動該領域的發展。

除了科學進展之外，本報告還概述了該領域的商業性發展，包括競爭定位、技術平台、合作策略、授權策略、投資趨勢和市場機會。報告全面闡述了科學進步和商業策略如何融合，共同塑造下一代蛋白水解療法，為有意進入這一快速發展治療領域的公司提供了關鍵資訊。

Global PROTAC Targeted Protein Degraders Market Opportunity > USD 1500 Million By 2030
Comprehensive Insight On PROTAC Drugs In Clinical Trials: >140 Drugs
Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase
Fast Track & Orphan Designation Status Insight
PROTAC Drugs Market Trends Insight By Region & Indication
Proprietary Technology Platforms By Companies
Competitive Landscape

Need For PROTAC Therapies & Why This Report?

Specific targeted protein degradation via PROTACs is one of the most promising breakthroughs in drug discovery in recent years. Being capable of selectively removing disease causing proteins instead of just targeting their function, PROTACs have provided additional tools for addressing hard to treat targets across various disease areas such as oncology, immunology, neuroscience, infections, and more. The area has progressed from being a promising academic concept to a well-established approach for developing novel therapeutics based on the advances in medicinal chemistry, structure biology, computational drug discovery, linker design, and E3 ligase biology. Approval of the first FDA approved PROTAC and the advancement of pipelines of clinical-stage drugs have further validated the platform as a novel approach for drug development.

In this report, we provide a thorough review of the global PROTAC market landscape that includes technology platforms, drug discovery approaches, competitive environment, clinical development, partnering deals, and commercial prospects. It evaluates the influence of key players such as pharmaceutical companies, biotech firms, universities, and technology suppliers on the future of targeted protein degradation. Furthermore, this report reveals many emerging business opportunities in the field of targeted protein degradation that can be of interest for investments, partnerships, licensing, and portfolio extension. This is a valuable source of information for pharmaceutical professionals and investors who want to know more about one of the most promising trends in precision medicine.

Clinical Trials Insight Included In Report

Clinical development continues to be a very powerful measure of the commercial prospects of PROTAC drugs in the future. In recent times, there have been many drug candidates that have been moved from preclinical studies to clinical trials across several therapeutic categories, showing that confidence in the technology is increasing. The report provides an extensive summary of the current pipeline of clinical drugs, including clinical programs at various stages of development, along with information regarding indications, target molecules, sponsors, mode of action, phases of development, geographical spread, etc.

The report analyzes monotherapy and combination therapy approaches currently explored within oncology and other therapy areas. Special focus is dedicated to combinations involving endocrine therapy, kinase inhibitors, immunotherapies, targeted therapies, chemotherapy, and emerging drug modalities used to increase efficacy and treat resistance. Moreover, details on companies and organizations that sponsor, develop, conduct preclinical and clinical trials of targeted protein degradation therapies are provided in order to provide insight into the current clinical ecosystem.

Major Companies Developing PROTAC Therapies

Currently, the competitive environment in the field of targeted protein degradation features involvement of large pharmaceutical companies, promising biotech firms, contract research organizations, and top academic centers. The companies that pioneered in developing such therapies proved that degrader drugs were orally available and capable of being clinically used in the form of protein degradation, which became the basis of the current pipeline growth. Ever since, many companies have joined the race in the area and developed new proprietary platforms, novel E3 ligases, tissue specific degraders, brain-permeable compounds, and new degradation technologies.

In addition to the development of new drug candidates by different companies, a wide variety of firms are also involved in investment in enabling technologies like computational drug design, artificial intelligence, proteomics, structural biology, ligand discovery, and biomarkers. Licensing, collaborations, venture funding, and acquisitions keep strengthening the business potential of this field while pushing innovations across several therapeutic areas.

Technology Platforms, Collaborations & Agreements

Technology platforms have emerged as one of the key differentiators in the targeted protein degradation space. Companies are not only designing their drug candidates but have created discovery engines that can deliver various programs involving different classes of proteins. These platforms employ medicinal chemistry, structural biology, computational modeling, linker design and optimization, ligand discovery, artificial intelligence, proteomics, pharmacokinetic modeling, and E3 ligase biology for enhancing the speed of discovery and optimization of degraders.

Another interesting example is PROTAC Discovery Engine from Arvinas that combines target biology, proprietary E3 ligase know how, high throughput chemistry, structural biology, artificial intelligence, ligand discovery technology, and translational pharmacology into one discovery engine. The platform allowed the company to create multiple clinical candidates, including oral bioavailable and brain penetrating compounds, as well as develop the first FDA approved drug that works via PROTAC mechanism.

Strategic collaborations became another significant element in innovation. More and more collaborations among pharmaceutical companies, biotech companies, academic labs, artificial intelligence companies, and contract research organizations join forces combining expertise in target discovery, medicinal chemistry, clinical development, biomarker development, and precision medicine. This trend is expected to continue to define the future of the PROTAC landscape.

Report Indicating Future Direction Of PROTAC Therapies

Moreover, the future of targeted protein degradation is anticipated to be much broader than the first generation of drugs targeting various cancers. Discovery of new E3 ligases, development of tissue-specific degradation tools, enhanced pharmacodynamics, central nervous system delivery, improved oral bioavailability, and selection of patients based on precise biomarkers will contribute to expansion of application areas for PROTACs in many diseases. Recent developments like molecular glues, artificial intelligence in degrader discovery, and innovative delivery technologies will also help in expansion of this field even further.

Besides scientific advancement, the report reviews the commercial development of the space, including competitive positioning, technology platform, partnership strategy, licensing strategy, investment trend, and market opportunity. The report provides a holistic view of how scientific advancement and commercial strategy are converging to define the future generation of protein degradation therapies, providing important information for companies interested in entering this fast-moving therapeutic field.

1. Introduction To PROTAC Technology

1.1 Overview Of PROTAC Technology
1.2 Development & Evolution of PROTACs

2. PROTAC Therapies Potential In Cancer Therapeutics

2.1 Importance As Targeted Therapy
2.2 Comparison With Conventional Treatment Methods

3. Clinical Overview of PROTAC Technology

3.1 Components Of PROTAC Molecules
3.2 Mechanism Of Action

4. FDA Approved PROTAC: Veppanu (Vepdegestrant ) - Clinical & Pricing insight

4.1 Overview & Patent Insight
4.2 Pricing & Dosing

5. Global PROTAC Drugs Clinical Trials Insight Overview

5.1 By Company
5.2 By Country
5.3 By Phase
5.4 By Indication

6. Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase III

7. Marketed PROTAC Drugs Clinical Trials Insight By Company, Country & Indication

8. PROTAC Technology Platforms By Companies

9. Global PROTAC Drug Market Trends Insight

9.1 Current Market Overview
9.2 Future Clinical & Commercial Opportunities

10. Global PROTAC Drug Market Trends By Region

10.1 US
10.2 South Korea
10.3 China

11. Global PROTAC Drug Market Trends By Indication

11.1 Cancer
11.2 Autoimmune & Inflammatory Diseases
11.3 Infectious Diseases
11.4 Neurodegenerative Diseases
11.5 Cardiovascular Diseases

12. Global PROTAC Drugs Market Dynamics & Outlook

12.1 Drivers & Opportunities
12.2 Challenges & Restraints

13. Competitive Landscape

13.1 Arvinas
13.2 Axter Therapeutics
13.3 Beactica
13.4 BioTheryX
13.5 BeOne Medicines
13.6 EnhancedBio
13.7 InSilico Medicine
13.8 Suzhou Kintor Pharmaceuticals
13.9 Ubix Therapeutics
13.10 Uppthera

簡介目錄圖表

List of Figures

Figure 1-1: PROTACs - Evolution Across Generations
Figure 1-2: PROTACs - Major Developmental Milestones Over The Years
Figure 2-1: PROTACs - Advantages As Cancer Target Therapy
Figure 3-1: PROTAC - Typical Structure
Figure 3-2: PROTACs - Mechanism Of Action
Figure 5-1: Global - Number Of PROTAC Drugs In Clinical Trials By Company, 2026 Till 2030
Figure 5-2: Global - Number Of PROTAC Drugs In Clinical Trials By Country, 2026 Till 2030
Figure 5-3: Global - Number Of PROTAC Drugs In Clinical Trials By Phase, 2026 Till 2030
Figure 5-4: Global - Number Of PROTAC Drugs In Clinical Trials By Indication, 2026 Till 2030
Figure 8-1: Cullgen's Targeted Protein Degrader Molecule
Figure 8-2: Cullgen's Degrader - Mechanism Of Action
Figure 8-3: PROTAC(R) Discovery Engine - Arvinas
Figure 8-4: Degraducer Technology - Ubix Therapeutics
Figure 8-5: SpeedUPP Platform - UPPTHERA
Figure 8-6: DaTProD Platform - HealZen Therapeutics
Figure 9-1: Global - PROTA Therapy Market Projection (US$ Million), 2026 & 2030
Figure 11-1: VERITAC-2 Phase III (NCT05654623) Study - Initiation & Completion Year
Figure 11-2: VERITAC-3 Phase III (NCT05909397) Study - Initiation & Completion Year
Figure 11-3: I-SPY-2 Phase II (NCT01042379) Study - Initiation & Completion Year
Figure 11-4: ARV-393-101 Phase I (NCT06393738) Study - Initiation & Completion Year
Figure 11-5: BROADEN2 Phase II (NCT07217015) Study - Initiation & Completion Year
Figure 11-6: BREADTH Phase II (NCT07323654) Study - Initiation & Completion Year
Figure 11-7: Viral Protein Targets For Targeted Degradation
Figure 11-8: Selective Degradation Of Disease-Causing Protein Aggregates
Figure 11-9: Neurodegenerative Diseases & Major Protein Targets
Figure 11-10: Potential Applications Of Protein Degradation In Cardiovascular Diseases
Figure 12-1: Global PROTAC Drugs Market - Drivers & Opportunities
Figure 12-2: Global PROTAC Drugs Market - Challenges & Restraints